Northern Trust Corp Raises Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Northern Trust Corp increased its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 418,745 shares of the company’s stock after buying an additional 12,374 shares during the quarter. Northern Trust Corp owned about 0.77% of Voyager Therapeutics worth $2,374,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Rhumbline Advisers raised its position in Voyager Therapeutics by 3.4% in the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock valued at $405,000 after purchasing an additional 2,354 shares during the period. Empowered Funds LLC raised its position in Voyager Therapeutics by 5.3% in the fourth quarter. Empowered Funds LLC now owns 47,206 shares of the company’s stock valued at $268,000 after purchasing an additional 2,397 shares during the period. Wells Fargo & Company MN raised its position in Voyager Therapeutics by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock valued at $378,000 after purchasing an additional 2,400 shares during the period. Picton Mahoney Asset Management raised its position in Voyager Therapeutics by 71.1% in the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after purchasing an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after purchasing an additional 3,077 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Stock Performance

Shares of NASDAQ VYGR opened at $2.92 on Monday. The firm has a market cap of $161.58 million, a price-to-earnings ratio of 4.11 and a beta of 0.95. Voyager Therapeutics, Inc. has a 1 year low of $2.75 and a 1 year high of $9.55. The stock’s 50-day simple moving average is $3.36 and its 200-day simple moving average is $4.65.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.18). The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. As a group, research analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Buying and Selling

In related news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the transaction, the chief executive officer now directly owns 430,931 shares in the company, valued at approximately $1,478,093.33. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on VYGR. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the company an “overweight” rating in a research report on Wednesday, March 12th. Canaccord Genuity Group dropped their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $13.39.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.